Pretreatment biopsy analysis of DAB2IP identifies subpopulation of high‐risk prostate cancer patients with worse survival following radiation therapy

Decreased expression of tumor suppressor DAB2IP is linked to aggressive cancer and radiation resistance in several malignancies, but clinical survival data is largely unknown. We hypothesized that pretreatment DAB2IP reduction would predict worse prostate cancer‐specific survival (PCSS). Immunohisto...

Descripción completa

Detalles Bibliográficos
Autores principales: Jacobs, Corbin, Tumati, Vasu, Kapur, Payal, Yan, Jingsheng, Xie, Xian‐Jin, Hannan, Raquibul, Hsieh, Jer‐Tsong, Kim, Dong Wook Nathan, Saha, Debabrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940806/
https://www.ncbi.nlm.nih.gov/pubmed/26471467
http://dx.doi.org/10.1002/cam4.554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4940806/
https://www.ncbi.nlm.nih.gov/pubmed/26471467
http://dx.doi.org/10.1002/cam4.554

Ejemplares similares